Nexus AG

  • WKN: 522090
  • ISIN: DE0005220909
  • Land: Deutschland

Nachricht vom 10.06.2015 | 14:21

Nexus AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


NEXUS AG 

10.06.2015 14:21

Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

On June 09, 2015, FIL Investments International, Hildenborough, United Kingdom has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on NEXUS AG, Villingen-Schwenningen, Germany, have fallen below the 5% threshold of the Voting Rights on June 09, 2015 and on that day amounted to 4.68% (this corresponds to 736116 Voting Rights). 4.68% of Voting Rights (this corresponds to 736116 Voting Rights) are attributed to the company in accordance with Article 22, Section 1, Sentence 1, No. 6 of the WpHG (German Securities Trading Act). Attributed Voting Rights are held by the following shareholders, whose share of the Voting Rights in NEXUS AG amounts to 3 percent or more: Fidelity Funds SICAV. 10.06.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: NEXUS AG Auf der Steig 6 78052 Villingen-Schwenningen Germany Internet: www.nexus-ag.de End of Announcement DGAP News-Service

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Linde Included in Dow Jones Sustainability World Index for 19th Consecutive Year

02. Dezember 2021, 12:00

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021